Italy's Move To Fund Off-label Avastin Use In AMD May Be Illegal, Pharma Groups Say
This article was originally published in The Pink Sheet Daily
Executive Summary
EFPIA, Novartis and Roche believe that a decision by the Italian regulatory authority, AIFA to allow reimbursement for the off-label use of Avastin in place of Lucentis may be against EU law.